SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Summary

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Cancer, Metastatic
• Cancer
• Cancer of Pancreas
• Cancer of Liver
• Cancer of Stomach
• Cancer Liver
• Cancer of Rectum
• Cancer of Kidney
• Cancer of Esophagus
• Cancer of Cervix
• Cancer of Colon
• Cancer of Larynx
• Cancer, Lung
• Cancer, Breast
• Cancer, Advanced
• Cancer Prostate
• Cancer of Neck
• Cancer of Skin
• Neuroendocrine Tumors
• Carcinoma
• Mismatch Repair Deficiency
• BRCA Gene Rearrangement
• Non Hodgkin Lymphoma
• Leukemia
• Non Small Cell Lung Cancer
• Cholangiocarcinoma
• Glioblastoma
• Central Nervous System Tumor
• Melanoma
• Urothelial Carcinoma
• Bladder Cancer
• Ovarian Cancer
• Endometrial Cancer
• Testicular Cancer
• Breast Cancer
• COVID
• Myelofibrosis
• Myeloproliferative Neoplasm
• Myeloproliferative Disorders
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Myelodysplastic Syndromes

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

Any age

Sex

All

Healthy volunteers

Not accepted

Sponsor

Massive Bio, Inc.

Last updated on ClinicalTrials.gov

October 28, 2025

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites